产品简介:
Denosumab is a fully human sequence IgG2 monoclonal antibody that inhibits bone resorption by blocking the activity of receptor activator of nuclear factor-κB ligand (RANKL).
别名:Denosumab;地诺单抗
分子式:C6404H9908N1724O2004S50 分子量:144.71KD
产品形式:蛋白原液。每种装于冻存管中,单抗质量为标示数量1MG或者5MG,体积根据其浓度不同略有不同。
质量标准:
Non-reduced CE-SDS:………………………………………….>90%;
SEC-HPLC:………………………………………………………….>95%;
Bacterial Endotoxins Test:…………………………………. .<10EU/ml
Residual Proteins of Host Cell: ……………………………. <100 ng/mg
Exogenous residual DNA: …………………………………. . <100pg/mg
Residual Protein A: ……………………………………………. .<100 ng/mg
Biological Activity:………………………………………….……. .80% to 125% of standard
储存条件:
-70 ± 15℃for long-term storage, 2-8℃for short-term storage, away from light.
运输条件:
干冰运输
使用建议:
- meilunbio提供的产品为蛋白原液形式。每种装于冻存管中,单抗质量为标示数量1MG或者5MG,体积根据其浓度不同略有不同。
- 使用前可以根据自己实验需求进行稀释,溶剂建议用去离子无菌水(meilunbio货号MA0028,去离子无菌水(细胞培养用水))或者PBS(meilunbio货号MA0015PBS(1X),细胞培养级)。
- 不建议使用含有防腐成分的稀释液进行稀释,会增加细胞或者动物毒性。
- 稀释前,计算加入多少体积溶剂,请参考购买批次质检单上蛋白浓度,或者询问我司,
- 举例,质检单显示该批次单抗蛋白原液蛋白浓度为 50mg/ml
对应5MG包装的蛋白原液体积为5mg(质量)/50mg/ml(浓度)=0.1ML,
实验需求蛋白浓度为10mg/ml, 需要稀释倍数为 50/10=5, 则需要加入0.4ML,即400ul PBS或者无菌去离子水即可。
若给药量为固定质量值,比如单次给药0.5MG,对应蛋白原液给药体积为10ul,建议稀释后,提高给药体积降低误差,因为注射器或者移液器吸头残留会影响实验效果。 - 稀释后的蛋白溶液,可于2-8度冷藏避光保存不超过2周,不建议长期储存。
- 避免反复冻融,每次冻融蛋白活性会降低约5%左右。
描述 | Denosumab is a fully human sequence IgG2 monoclonal antibody that inhibits bone resorption by blocking the activity of receptor activator of nuclear factor-κB ligand (RANKL). |
靶点 | RANK Ligand |
Application | Denosumab is a fully human sequence IgG2 monoclonal antibody that inhibits bone resorption by blocking the activity of receptor activator of nuclear factor-κB ligand (RANKL). RANKL is a TNF family protein that is expressed in both secreted and cell surface forms by a variety of bone marrow cell types andmediates bone resorption through its receptor (RANK),which is found on osteoclasts and osteoclast precursors . Denosumab was discovered using XenomouseTM transgenic mice comprising human immunoglobulin genes. The antibody is approved for treatment of postmenopausal women with osteoporosis at high risk for fracture, and for the prevention of skeletal-related events in patients with bone metastases from solid tumors. Denosumab competes directly with bisphosphonates such as alendronic acid in postmenopausal osteoporosis and with zoledronic acid in both of these indications. It has been shown to have comparable efficacy and safety to bisphosphonates with some tolerability and patient acceptability advantages. |
产品编号 | 品名. | Target |
---|---|---|
MB2806 | aflibercept | VEGFR |
MB2786 | Alemtuzumab | CD52 |
MB2787 | Alirocumab | PCSK9 |
MB2789 | Avelumab | PDL-1 |
MB2790 | Atezolizumab | PDL-1 |
MB2791 | Bevacizumab | VEGF |
MB2792 | Cetuximab | EGFR |
MB2803 | Daratumumab | CD38 |
MB2784 | Adalimumab | TNF-α |
MB2023 | Eculizumab | 补体蛋白(C5) |
MB2795 | Etanercept | TNF |
MB2797 | Evolocumab | PCSK9 |
MB2773 | Infliximab | TNF-α |
MB2769 | Ipilimumab | CTLA-4 |
MB2772 | Matuzumab | EGFR |
MB2766 | Mepolizumab | IL-5 |
MB2767 | Nivolumab | PD-1 |
MB2774 | Obinutuzumab | CD20 |
MB2776 | Ofatumumab | CD20 |
MB2777 | Omalizumab | IgE |
MB2781 | Panitumumab | EGFR |
MB2761 | Pembrolizumab | PD-1 |
MB2762 | Pertuzumab | HER2 |
MB2763 | Ranibizumab | VEGFR |
MB2938 | Ramucirumab | VEGFR |
MB2749 | Rituximab | CD20 |
MB2757 | Secukinumab | IL-17 |
MB2751 | Tocilizumab/Atlizumab | IL-6 receptor |
MB2753 | Trastuzumab | ErbB2 |
MB2758 | Ustekinumab | IL-12 |